Literature DB >> 19067496

Complications of dysglycemia and medical costs associated with nondiabetic hyperglycemia.

Gregory A Nichols1, Bhakti Arondekar, William H Herman.   

Abstract

OBJECTIVE: To estimate the prevalence of complications associated with diabetes in patients with hyperglycemia below the threshold for diabetes, and to evaluate the associated medical costs. STUDY
DESIGN: Retrospective observational cohort study.
METHODS: We used fasting and random glucose test results, and a previously validated predictive equation to assign 26,111 nondiabetic patients to the following categories: normoglycemia, isolated impaired fasting glucose (I-IFG), isolated impaired glucose tolerance (I-IGT), or IFG with IGT (IFG/IGT). We identified microvascular complications (retinopathy, neuropathy, nephropathy) and macrovascular complications (cardiovascular disease, stroke, peripheral vascular disease, heart failure) commonly associated with diabetes from electronic medical records. We then calculated and compared the impacts of hyperglycemia and its complications in terms of age/sex-adjusted mean annual medical care costs.
RESULTS: Complications were most prevalent among the I-IGT and IFG/IGT patients -- more than half (51.1% in each group) had at least 1 complication compared with 33.9% of normoglycemic patients (P <.001 for both comparisons). Macrovascular complications added $3,863 (P <.0001) to annual age/sex-adjusted per-person medical costs; microvascular complications added $1,874 (P <.0001). I-IGT ($716; P <.0001) and IFG/IGT ($438; P = .009) independently added to costs after controlling for presence of any complication.
CONCLUSIONS: For many patients, complications associated with hyperglycemia appear to develop before diabetes diagnosis. Complications add significantly to the cost of medical care at hyperglycemic levels below the threshold for diabetes. However, the increased prevalence of complications did not completely explain the observed differences in age/sex-adjusted medical care costs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19067496

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  14 in total

1.  The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications.

Authors:  Chun Zeng; Xiaoyun Shi; Baojun Zhang; He Liu; Lianjun Zhang; Wenjun Ding; Yong Zhao
Journal:  J Mol Med (Berl)       Date:  2011-10-01       Impact factor: 4.599

Review 2.  The economics of diabetes prevention.

Authors:  William H Herman
Journal:  Med Clin North Am       Date:  2011-03       Impact factor: 5.456

3.  Unrecognized glucose intolerance is common in pulmonary arterial hypertension.

Authors:  Meredith E Pugh; Ivan M Robbins; Todd W Rice; James West; John H Newman; Anna R Hemnes
Journal:  J Heart Lung Transplant       Date:  2011-04-13       Impact factor: 10.247

4.  Prediabetes Deserves More Attention: A Review.

Authors:  Yakubu Lawal; Fatima Bello; Yazid Suleiman Kaoje
Journal:  Clin Diabetes       Date:  2020-10

5.  Glucose, obesity, metabolic syndrome, and diabetes relevance to incidence of heart failure.

Authors:  Tamara B Horwich; Gregg C Fonarow
Journal:  J Am Coll Cardiol       Date:  2010-01-26       Impact factor: 24.094

6.  Metabolic syndrome components are associated with future medical costs independent of cardiovascular hospitalization and incident diabetes.

Authors:  Gregory A Nichols; Edward J Moler
Journal:  Metab Syndr Relat Disord       Date:  2010-12-18       Impact factor: 1.894

7.  A new public health tool for risk assessment of abnormal glucose levels.

Authors:  Guozhong He; Tetine Sentell; Dean Schillinger
Journal:  Prev Chronic Dis       Date:  2010-02-15       Impact factor: 2.830

8.  Cardiovascular disease, heart failure, chronic kidney disease and depression independently increase the risk of incident diabetes.

Authors:  G A Nichols; E J Moler
Journal:  Diabetologia       Date:  2010-11-24       Impact factor: 10.122

9.  Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes.

Authors:  Abd A Tahrani; Anthony H Barnett
Journal:  Diabetes Ther       Date:  2011-01-19       Impact factor: 2.945

10.  Age at menarche and its association with dysglycemia in Korean middle-aged women.

Authors:  Tae-Hwa Baek; Nam-Kyoo Lim; Min-Ju Kim; Joungwon Lee; Seungho Ryu; Yoosoo Chang; Yuni Choi; Hyun-Young Park
Journal:  Menopause       Date:  2015-05       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.